4 Reasons to Go Long On Merrimack Pharmaceuticals Inc. [MACK]

Merrimack Pharmaceuticals Inc. [MACK] shares are up more than 56.59% this year and recently decreased -0.06% or -$0.39 to settle at $6.10. Analysts expect MACK to grow earnings at a 5.60% annual rate over the next 5 years. MACK has a short ratio of 0.40. This implies that the market is currently less bearish on the outlook for MACK.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 5, November 2020, Merrimack Reports Third Quarter 2020 Financial Results. According to news published on Yahoo Finance, Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its third quarter 2020 financial results for the period ended September 30, 2020.

Analyst Birdseye View:

The most recent analyst activity for Merrimack Pharmaceuticals Inc. [NASDAQ:MACK] stock was on May 27, 2016, when it was Initiated with a Neutral rating from Robert W. Baird, which also raised its 12-month price target on the stock to $8. On December 23, 2015, Mizuho Reiterated a Buy rating and plunged its price target on this stock from $16 to $13. On October 27, 2015, Oppenheimer Reiterated an Outperform rating and increased its price target from $13 to $15. On April 21, 2015, Mizuho Reiterated a Buy rating and increased its price target to $16. On October 10, 2014, Oppenheimer Resumed an Outperform rating and boosted its amount target on this stock to $11. On July 08, 2014, Brean Capital Resumed a Buy rating and boosted its target amount on this stock to $16. On June 20, 2014, Oppenheimer Reiterated an Outperform rating and improved its amount target to $8.50.

In the past 52 weeks of trading, this stock has oscillated between a low of $1.49 and a peak of $7.10. Right now, the middling Wall Street analyst 12-month amount mark is $4.00. At the most recent market close, shares of Merrimack Pharmaceuticals Inc. [NASDAQ:MACK] were valued at $6.10. According to the average price forecast, investors can expect a potential return of 0.0%.


Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 5.74 points at 1st support level, the second support level is making up to 5.39. But as of 1st resistance point, this stock is sitting at 6.40 and at 6.70 for 2nd resistance point.

Merrimack Pharmaceuticals Inc. [MACK] reported its earnings at $0.3 per share in the fiscal quarter closing of 9/29/2018. The Analysts for Wall Street were expecting to report its earnings at -$0.27/share signifying the difference of 0.57 and 211.10% surprise value. Comparing the previous quarter ending of 6/29/2018, the stated earnings were -$1.33 calling estimates for -$1.28/share with the difference of -0.05 depicting the surprise of -3.90%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Merrimack Pharmaceuticals Inc. [NASDAQ:MACK] is 8.40. Likewise, the Quick ratio is also the same, showing Cash ratio at 5.99. Now if looking for a valuation of this stock’s amount to book ratio is 2.43.

Insider Stories

The most recent insider trade was by Levy Noah G., Director, and it was the purchase of 29776.0 shares on Dec 01. Andersen Eric, the Director, completed a purchase of 69088.0 shares on Nov 24. On Nov 24, Levy Noah G., Director, completed a purchase of 69087.0 shares.